SAN DIEGO, September 20, 2013 – Profil® Institute for Clinical Research, Inc., a company providing science-driven early phase diabetes and obesity clinical research, will present clinical and experimental diabetes and insulin-related research at the European Association for the Study of Diabetes (EASD) 49th Annual Meeting being held September 23-27 in Barcelona, Spain.
Oral presentation by Profil Institute’s Dr. Marcus Hompesch:
Thursday, September 28, Dr. Marcus Hompesch, Profil Institute’s CEO will present Effect of a dual agonist of glucagon-like peptide-1/glucose-dependent insulinotropic peptide (MAR701) on insulin secretion rate and gastric emptying in healthy volunteers. Author Block: M. Hompesch, L. Morrow, K. Win, L. Vignati, J. Hauptmann.
A webcast will be available at http://www.easdvirtualmeeting.org/contentsessions/214.
Profil Institute’s poster presentations include:
Poster #742: Luseogliflozin (TS-071), a novel, potent, and selective inhibitor of SGLT2 is safe and well-tolerated in type 2 diabetes mellitus and showed dose-dependent PK/PD in both US/Japanese ethnicities. Authors: L.A. Morrow, Samukawa, M.J. Guttierrez, Y. Tanaka, H.D. Sabia, K. Shimasaki, H. Ochiai, S. Yasuda, Y. Samukawa, M. Hompesch, D.P. Rossignol.
An abstract is available at http://www.easdvirtualmeeting.org/resources/722.
Poster #796: Brown adipose tissue metabolic activity assessed with FDG-PET/CT correlates with BMI and glucose tolerance in insulin resistant subjects. Authors: M.S. Buchsbaum, L. Morrow, D. Meyers, A. Krentz, G. Peterson, T. Swan, A. DeCastro, M. Hompesch, D. Laurent.
An abstract is available at http://www.easdvirtualmeeting.org/resources/3868.
Poster #925: Insulin degludec provides similar pharmacokinetic and pharmacodynamic responses in Black, White and Hispanic/Latino patients with type 2 diabetes. Authors: M. Hompesch, L. Morrow, E. Watkins, C. Roepstorff, H.F. Thomsen, H.L. Haahr.
An abstract is available at http://www.easdvirtualmeeting.org/resources/899.
Poster #1011: Effect of exogenous glucagon vs spontaneous recovery from hypoglycaemia in subjects with type 2 diabetes treated with a novel glucokinase activator AZD1656 and metformin. Authors: A. Krentz, L. Morrow, M. Petersson, E. Norjavaara, M. Hompesch.
Poster is available to view at http://www.easdvirtualmeeting.org/resources/6600.
Poster #1015: Metabolic effects and safety of two selective 11β-HSD1 inhibitors (RO5093151 (RO151) and RO5027838 (RO838) in metformin-treated patients with type 2 diabetes. Authors: S. Fuerst-Recktenwald, T. Heise, M. Hompesch, T. Pieber, H.-U. Haering, C. Kapitza, M. Abt, M. Ramsauer, L. Morrow.
An abstract is available at http://www.easdvirtualmeeting.org/resources/3909.
Poster #1030: LY2605541 exhibits a flatter glucodynamic profile than insulin glargine at steady state in subjects with type 1 diabetes. Author block: L.A. Morrow, M. Hompesch, S.J. Jacober, S.L. Choi, Y. Qu, V. Sinha.
Poster is available to view at http://www.easdvirtualmeeting.org/resources/6856.
About EASD’s Annual Meeting :
More information can be found at http://www.easd.org/images/easdwebfiles/annualmeeting/49thmeeting/index.html.
About Profil® Institute for Clinical Research, Inc.
Profil Institute is a Center of Excellence performing early phase clinical research of drugs and devices for diabetes and obesity and providing scientific support for metabolic drug target profiling, clinical development planning, publication activities and the establishment of scientific advisory boards. The company’s scientific expertise, metabolic clinical research methodologies, and automated glucose clamp technology enable Profil Institute to execute highly complex studies and have led Profil Institute to be a highly regarded clinical research institute for early phase diabetes drug studies. Profil Institute has been involved with every clinically relevant drug class in diabetes and in more than 200 clinical studies since the company’s inception in 2004. For more information visit www.profilinstitute.com.
For further information, please contact: